Silver Book Fact

Cost-savings associated with optimal anticoagulation in AFib patients

If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct costs.

Caro, JJ. An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation. Am J Managed Care. 2004; 10(14): S451-61. An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation

Reference

Title
An Economic Model of Stroke in Atrial Fibrillation: The cost of suboptimal oral anticoagulation
Publication
Am J Managed Care
Publication Date
2004
Authors
Caro, JJ
Volume & Issue
Volume 10, Issue 14
Pages
S451-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • t-PA cost savings
    The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
  • Effectiveness of pacemaker/defibrillators to control AFib
    Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • Stroke risk reduction from thrombin inhibitor in AFib patients
    A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.